Small Caps expert Tim Boreham's (he is one of Australia’s best-known small cap analysts and business journalists) * article 28 January 2018 (https://unauthorised investment adv...al&utm_source=twitter.com&utm_campaign=buffer)
* Undervalued -Dr Bill Ketelbey reckons that, globally, a phase II Alzheimer’s triallist attracts an average market valuation of $US800 million (AU$992 million). Given Actinogen’s lowly $30 million market cap, he contends the company is undervalued.
* Xanadu and beyond - Xanamem’s opportunities lie with diabetes-related cognitive impairment, post-traumatic stress disorder, Parkinson’s disease, epilepsy, schizophrenia and post myocardial infarction.All of these are related to elevated levels of the cortisol “stress hormone”.
Small Caps expert Tim Boreham's (he is one of Australia’s...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.6¢ |
Change
-0.003(7.69%) |
Mkt cap ! $97.64M | |||
| Open | High | Low | Value | Volume |
| 3.7¢ | 3.9¢ | 3.6¢ | $151.2K | 4.072M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 3271718 | 3.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.7¢ | 125725 | 3 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| ACW (ASX) Chart |